BCRX three-lens brief
Evidence-based stock research on BCRX. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- P/E of 7.0 — trading at a value multiple.
- Analyst mean target $20.45 — 167% above current (11 analysts).
- Reported earnings on 2026-11-04.
BCRX closed at $7.65 (+1.59%) as of 2026-11-12. Market cap: $1.97B. P/E (trailing) 7.0. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 7.0 — trading at a value multiple.; analyst mean target $20.45 — 167% above current (11 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $180.29M, net income $37.92M, free cash flow $301.09M.
Why three lenses on BCRX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BCRX across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BCRX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BCRX brief"></iframe>